Insulin, epidermal growth factor and fibroblast growth factor elicit distinct patterns of protein tyrosine phosphorylation in BC3H1 cells.
The polypeptides which are phosphorylated at tyrosine residues in the murine muscle-like cell line, BC3H1, in response to insulin, epidermal growth factor (EGF) and fibroblast growth factor (FGF) were detected by immunoblotting with antiphosphotyrosine antibodies. Each ligand elicited the tyrosine phosphorylation of a characteristic, largely nonoverlapping set of polypeptide substrates, as classified by subunit Mr, pI, behavior on subcellular fractionation and adsorption to lectin (what germ agglutinin-Sepharose) columns. The dose-response curves for all stimulated tyrosine phosphorylations elicited by a single ligand were superimposable. By contrast, the temporal pattern of the responses elicited by each ligand differed in regard to speed of onset and persistence of the stimulation. Phosphorylation in response to insulin was maximal in a virtually instantaneous fashion and was fully maintained for at least 30 min. The response to EGF increased steadily over the initial 15-60 s to peak values, and fell progressively thereafter. FGF-stimulated phosphorylation was not detectable until 4 min after FGF addition, abruptly rose to maximal within the next 30 s, and declined subsequently. Exposure of BC3H1 cells to active phorbol esters prior to hormone addition altered the response to hormones in a differential fashion. FGF responses were abolished, EGF responses were partially inhibited, whereas the response to insulin was unaffected. Thus, acting on a single cell, insulin, EGF and FGF each mediate the tyrosine phosphorylation of a characteristic, largely nonoverlapping array of polypeptide substrates, indicating that each of these receptor tyrosine kinases exhibits a fundamentally distinct substrate specificity. Differences in the kinetic and regulatory properties of the response to each ligand are also apparent, and reflect the differing regulatory properties of each receptor tyrosine kinase acting in situ.
Kyriakis
J M
JM
Medical Services and Diabetes Unit, Massachusetts General Hospital, Boston 02129.
Avruch
J
J
D000818:Animals; D002460:Cell Line / Q000187:drug effects; D015180:Electrophoresis, Gel, Two-Dimensional; D004815:Epidermal Growth Factor / Q000494:pharmacology*; D066246:ErbB Receptors / Q000378:metabolism; D005346:Fibroblast Growth Factors / Q000494:pharmacology*; D007328:Insulin / Q000494:pharmacology*; D051379:Mice; D009132:Muscles / Q000187:drug effects / Q000378:metabolism*; D010703:Phorbol Esters / Q000494:pharmacology; D010766:Phosphorylation; D011505:Protein-Tyrosine Kinases / Q000378:metabolism*; D013379:Substrate Specificity; D014443:Tyrosine / Q000378:metabolism*
D007328:Insulin; D010703:Phorbol Esters; D014443:Tyrosine; D005346:Fibroblast Growth Factors; D004815:Epidermal Growth Factor; D066246:ErbB Receptors; D011505:Protein-Tyrosine Kinases